



PCT/GB 2004 / 0 0 2 8 1 0



INVESTOR IN PEOPLE

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

22 JUL 2004

WIPO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

W. Evans

Dated 9 July 2004



The
Patent
Office

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1 JUL 2003

1. Your reference

PA 535

2. Patent application number

(The Patent Office will fill in this part)

0315457.2

02JUL03 E819501-1 C72481

P01/7700 0.00 0315457.2

3. Full name, address and postcode of the or of each applicant (underline all surnames)

CELLTECH R+D LIMITED
208 BATH ROAD
SLOUGH, BERKSHIRE
SL1 3WE

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

UK 08182305002

4. Title of the invention

BIOLOGICAL PRODUCTS

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

CELLTECH R+D LIMITED
208 BATH ROAD
SLOUGH, BERKSHIRE
SL1 3WE

Patents ADP number (if you know it)

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

Number of earlier application

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

YES

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

0

Description

27

Claim(s)

3

Abstract

0

Drawing(s)

5 + 5 fm.

10. If you are also filing any of the following, state how many against each item.

Priority documents

0

Translations of priority documents

0

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

0

Request for preliminary examination and search (Patents Form 9/77)

0

Request for substantive examination (Patents Form 10/77)

0

Any other documents (please specify)

0

11.

I/We request the grant of a patent on the basis of this application.
FOR AND ON BEHALF OF CELLTECH R+D LIMITED

Signature

A.J. Blanchard

Date

01/07/03

12. Name and daytime telephone number of person to contact in the United Kingdom

Dr. AMANDA BLANCHARD 01753 53465

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

BIOLOGICAL PRODUCTS

The present invention relates to improved antibody fragments and more specifically provides improved antibody fragments to which two or more effector molecules are attached and methods for their production.

The high specificity and affinity of antibody variable regions make them ideal diagnostic and therapeutic agents, particularly for modulating protein:protein interactions. Antibody fragments are proving to be versatile therapeutic agents, as seen by the recent success of products such as ReoPro®. The targeting function encoded in Fv, Fab, Fab', F(ab)₂ and other antibody fragments can be used directly or can be conjugated to one or more effector molecules such as cytotoxic drugs, toxins or polymer molecules to increase efficacy. For example, since these fragments lack an Fc region they have a short circulating half-life in animals but this can be improved by conjugation to certain types of polymer such as polyethylene glycol (PEG). Increasing the size of the conjugated PEG has been shown to increase the circulating half-life from minutes to many hours and modification of a Fab' with PEG ranging from 5kDa to 100kDa has been demonstrated (Chapman *et al.*, 1999, Nature Biotechnology, 17, 780-783; Leong *et al.*, 2001, Cytokine, 16, 106-119; Chapman, 2002, Advanced Drug Delivery Reviews, 54, 531-545). PEGylated antibody fragments such as CDP870 are currently undergoing clinical trials where the effect of the conjugated PEG is to bring the circulating half-life to acceptable levels for therapy.

Effector molecules may be attached to antibody fragments by a number of different methods, including through aldehyde sugars or more commonly through any available amino acid side-chain or terminal amino acid functional group located in the antibody fragment, for example any free amino, imino, thiol, hydroxyl or carboxyl group. The site of attachment of effector molecules can be either random or site specific.

Random attachment is often achieved through amino acids such as lysine and this results in effector molecules being attached at a number of sites throughout the antibody fragment depending on the position of the lysines. While this has been successful in some cases the exact location and number of effector molecules attached cannot be controlled and this can lead to loss of activity for example if too few are attached and/or loss of affinity if for example they interfere with the binding site (Chapman 2002 *Advanced Drug Delivery Reviews*, 54, 531-545). As a result, controlled site specific attachment of effector molecules is usually the method of choice.

Site specific attachment of effector molecules is most commonly achieved by attachment to cysteine residues since such residues are relatively uncommon in antibody fragments. Antibody hinges are popular regions for site specific attachment since these contain cysteine residues and are remote from other regions of the antibody likely to be involved in antigen binding. Suitable hinges either occur naturally in the fragment or may be created using recombinant DNA techniques (See for example US 5,677,425; WO98/25971; Leong *et al.*, 2001 *Cytokine*, 16, 106-119; Chapman *et al.*, 1999 *Nature Biotechnology*, 17, 780-783). Alternatively site specific cysteines may be engineered into the antibody fragment for example to create surface exposed cysteine(s) (US 5,219,996).

Where effector molecules are to be site specifically attached via a cysteine, the target thiol in the antibody fragment is often capped by a small fermentation related peptide product such as glutathione or deliberately capped by a chemical additive used during antibody fragment extraction and purification such as 5,5'-dithiobis (2-nitrobenzoic acid) (DTNB). These capping agents need to be removed to activate the target (hinge or surface) thiol. Antibody fragments have a native interchain disulphide bond between the heavy and light chain constant regions (C_H1 and C_L) that has generally been regarded as critical in maintaining the stability and binding properties of the antibody. As a result the activation of the target hinge or surface thiol must be carried out with some care such that the

inter C_L:C_H1 disulphide remains intact. Hence 'mild' reducing conditions are conventionally used to remove the thiol capping agent prior to reaction with the effector molecule. This is usually achieved by using thiol based reductants such as β-mercaptoethanol (β-ME), β-mercaptoethylamine (β-MA) and dithiothreitol (DTT). However, each of these reductants is known to be able to react with and stay attached to the cysteine which it is meant to reduce (Begg and Speicher, 1999 Journal of Biomolecular techniques, 10,17-20) thereby reducing the efficiency of effector molecule attachment. Hence, following reduction and reaction with effector molecules, a large proportion of the antibody fragments do not have any effector molecules attached and these have to be purified away from the antibody fragments that have the correct number of effector molecules attached. This poor efficiency of modification is clearly a disadvantage during the large-scale production of modified therapeutic antibody fragments where it is important that maximum production efficiency is achieved.

The present invention provides a new class of modified antibody fragments in which the heavy and light chains are not covalently linked. Despite the absence of any covalent linkage between the heavy and the light chain and the attachment of two or more effector molecules, the fragments of the invention perform comparably with wild type fragments in a number of *in vitro* and *in vivo* tests. Surprisingly these novel fragments have the same affinity for antigen and similar *in vivo* and *in vitro* stability as wild type fragments. A particular advantage of the fragments of the invention lies in their ease of manufacture, and in particular, their efficiency of manufacture. The fragments thus provide a low cost alternative to currently available fragments having inter-chain covalent linkages.

Thus according to the present invention there is provided an antibody Fab or Fab' fragment in which the heavy chain in the fragment is not covalently bonded to the light chain characterized in that two or more effector molecules are

attached to the fragment and at least one of said molecules is attached to a cysteine in the light chain or the heavy chain constant region.

5 The antibody fragment of the present invention may be any heavy chain and light chain pair having a variable (V_H/V_L) and constant region (C_H/C_L). The heavy and/or light chain constant region may be extended at its C-terminal with one or more amino acids. Particular examples include Fab and Fab' fragments.

10 The antibody fragment starting material for use in the present invention may be obtained from any whole antibody, especially a whole monoclonal antibody, using any suitable enzymatic cleavage and/or digestion techniques, for example by treatment with pepsin. Alternatively, the antibody starting material may be prepared by the use of recombinant DNA techniques involving the manipulation and re-expression of DNA encoding antibody variable and/or constant regions. Standard molecular biology techniques may be used to modify, add or delete
15 amino acids or domains as desired. Any alterations to the variable or constant regions are still encompassed by the terms 'variable' and 'constant' regions as used herein.

20 The antibody fragment starting material may be obtained from any species including for example mouse, rat, rabbit, pig, hamster, camel, llama, goat or human. Parts of the antibody fragment may be obtained from more than one species for example the antibody fragments may be chimeric. In one example the constant regions are from one species and the variable regions from another. The antibody fragment starting material may also be modified. In one example the variable region of the antibody fragment has been created
25 using recombinant DNA engineering techniques. Such engineered versions include those created for example from natural antibody variable regions by insertions, deletions or changes in or to the amino acid sequences of the natural antibodies. Particular examples of this type include those engineered variable region domains containing at least one CDR and optionally one or more
30 framework amino acids from one antibody and the remainder of the variable region domain from a second antibody. The methods for creating and

manufacturing these antibody fragments are well known in the art (see for example, Boss et al., US 4,816,397; Cabilly et al., US 6,331,415; Shrader et al., WO 92/02551; Ward et al., 1989, Nature, 341, 544; Orlandi et al., 1989, Proc.Natl.Acad.Sci. USA, 86, 3833; Riechmann et al., 1988, Nature, 322, 323; 5 Bird et al, 1988, Science, 242, 423; Queen et al., US 5,585,089; Adair, WO91/09967; Mountain and Adair, 1992, Biotechnol. Genet. Eng. Rev, 10, 1-142; Verma et al., 1998, Journal of Immunological Methods, 216, 165-181).

10 Fab' fragments for use in the present invention are extended at the C-terminus of the heavy chain by one or more amino acids. Typically the Fab' fragments for use in the present invention possess a native or a modified hinge region. The native hinge region is the hinge region normally associated with the C_H1 domain of the antibody molecule. A modified hinge region is any hinge that differs in length and/or composition from the native hinge region. Such hinges can 15 include hinge regions from other species, such as human, mouse, rat, rabbit, pig, hamster, camel, llama or goat hinge regions. Other modified hinge regions may comprise a complete hinge region derived from an antibody of a different class or subclass from that of the C_H1 domain. Thus, for instance, a C_H1 domain of class γ 1 may be attached to a hinge region of class γ 4. Alternatively, 20 the modified hinge region may comprise part of a natural hinge or a repeating unit in which each unit in the repeat is derived from a natural hinge region. In a further alternative, the natural hinge region may be altered by converting one or more cysteine or other residues into neutral residues, such as alanine, or by converting suitably placed residues into cysteine residues. By such means the 25 number of cysteine residues in the hinge region may be increased or decreased. In addition other characteristics of the hinge can be controlled, such as the distance of the hinge cysteine(s) from the light chain interchain cysteine, the distance between the cysteines of the hinge and the composition of other amino acids in the hinge that may affect properties of the hinge such as flexibility e.g. 30 glycines may be incorporated into the hinge to increase rotational flexibility or prolines may be incorporated to reduce flexibility. Alternatively combinations of

charged or hydrophobic residues may be incorporated into the hinge to confer multimerisation properties. Other modified hinge region may be entirely synthetic and may be designed to possess desired properties such as length, composition and flexibility.

5

A number of modified hinge regions have already been described for example, in US5,677,425, WO9915549, and WO9825971 and these are incorporated herein by reference. Typically hinge regions for use in the present invention will contain between 1 and 11 cysteines. Preferably between 1 and 4 cysteines and more preferably 1 or 2 cysteines. Particularly useful hinges include a modified human γ 1 hinge in which only one cysteine is present, comprising the sequence DKTHTCPP or DKHTCAA and those containing two cysteines comprising the sequence DKTHTCPPCPA or DKHTCAACPA.

10

The term effector molecule as used herein includes, for example, antineoplastic agents, drugs, toxins (such as enzymatically active toxins of bacterial or plant origin and fragments thereof e.g. ricin and fragments thereof) biologically active proteins, for example enzymes, other antibody or antibody fragments, synthetic or naturally occurring polymers, nucleic acids and fragments thereof e.g. DNA, RNA and fragments thereof, radionuclides, particularly radioiodide, radioisotopes, chelated metals, nanoparticles and reporter groups such as fluorescent compounds or compounds which may be detected by NMR or ESR spectroscopy.

20

Particular antineoplastic agents include cytotoxic and cytostatic agents for example alkylating agents, such as nitrogen mustards (e.g. chlorambucil, melphalan, mechlorethamine, cyclophosphamide, or uracil mustard) and derivatives thereof, triethylenephosphoramidate, triethylenethiophosphoramide, busulphan, or cisplatin; antimetabolites, such as methotrexate, fluorouracil, floxuridine, cytarabine, mercaptopurine, thioguanine, fluoroacetic acid, or fluorocitric acid, antibiotics, such as bleomycins (e.g. bleomycin sulphate),

30

doxorubicin, daunorubicin, mitomycins (e.g. mitomycin C), actinomycins (e.g. dactinomycin) plicamycin, calicheamicin and derivatives thereof, or esperamicin and derivatives thereof; mitotic inhibitors, such as etoposide, vincristine or vinblastine and derivatives thereof; alkaloids such as ellipticine; polyols such as taxicin-I or taxicin-II; hormones, such as androgens (e.g. dromostanolone or testolactone), progestins (e.g. megestrol acetate or medroxyprogesterone acetate), estrogens (e.g. dimethylstilbestrol diphosphate, polyestradiol phosphate or estramustine phosphate) or antiestrogens (e.g. tamoxifen); anthraquinones, such as mitoxantrone, ureas, such as hydroxyurea; hydrazines, such as procarbazine; or imidazoles, such as dacarbazine.

Chelated metals include chelates of di- or tripositive metals having a coordination number from 2 to 8 inclusive. Particular examples of such metals include technetium (Tc), rhenium (Re), cobalt (Co), copper (Cu), gold (Au), silver (Ag), lead (Pb), bismuth (Bi), indium (In), gallium (Ga), yttrium (Y), terbium (Tb), gadolinium (Gd), and scandium (Sc). In general the metal is preferably a radionuclide. Particular radionuclides include ^{99m}Tc , ^{186}Re , ^{188}Re , ^{58}Co , ^{60}Co , ^{67}Cu , ^{195}Au , ^{199}Au , ^{110}Ag , ^{203}Pb , ^{206}Bi , ^{207}Bi , ^{111}In , ^{67}Ga , ^{68}Ga , ^{88}Y , ^{90}Y , ^{160}Tb , ^{153}Gd and ^{47}Sc .

The chelated metal may be for example one of the above types of metal chelated with any suitable polyadentate chelating agent, for example acyclic or cyclic polyamines, polyethers, (e.g. crown ethers and derivatives thereof); polyamides; porphyrins; and carbocyclic derivatives.

In general, the type of chelating agent will depend on the metal in use. One particularly useful group of chelating agents in conjugates according to the invention, however, are acyclic and cyclic polyamines, especially polyaminocarboxylic acids, for example diethylenetriaminepentaacetic acid and derivatives thereof, and macrocyclic amines, e.g. cyclic tri-aza and tetra-aza derivatives (for example as described in International Patent Specification No.

WO 92/22583); and polyamides, especially desferriox-amine and derivatives thereof.

Synthetic or naturally occurring polymers include, for example optionally
5 substituted straight or branched chain polyalkylene, polyalkenylene, or
polyoxyalkylene polymers or branched or unbranched polysaccharides, e.g. a
homo- or hetero- polysaccharide such as lactose, amylose, dextran or glycogen.

Particular optional substituents which may be present on the above-mentioned
10 synthetic polymers include one or more hydroxy, methyl or methoxy groups.
Particular examples of synthetic polymers include optionally substituted straight
or branched chain poly(ethyleneglycol), poly(propyleneglycol), poly(vinylalcohol)
or derivatives thereof, especially optionally substituted poly(ethyleneglycol) such
as methoxypoly(ethyleneglycol) or derivatives thereof.

15

"Derivatives" as used herein is intended to include reactive derivatives, for
example thiol-selective reactive groups such as an α -halocarboxylic acid or
ester, e.g. iodoacetamide, an imide, e.g. maleimide, a vinyl sulphone or
disulphide maleimides and the like. The reactive group may be linked directly or
20 through a linker segment to the polymer. It will be appreciated that the residue
of such a group will in some instances form part of the product as the linking
group between the antibody fragment and the polymer.

The size of the polymer may be varied as desired, but will generally be in an
25 average molecular weight range from 500Da to 50,000Da, preferably from 5,000
to 40,000Da and more preferably from 10,000 to 40,000Da and 20,000 to
40,000Da. The polymer size may in particular be selected on the basis of the
intended use of the product. Thus, for example, where the product is intended
to leave the circulation and penetrate tissue, for example for use in the treatment
30 of a tumor, it may be advantageous to use a small molecular weight polymer, for
example with a molecular weight of around 5,000Da. For applications where the

product remains in the circulation, it may be advantageous to use a higher molecular weight polymer, for example having a molecular weight in the range from 25,000Da to 40,000Da.

- 5 Particularly preferred polymers include a polyalkylene polymer, such as a poly(ethyleneglycol) or, especially, a methoxypoly(ethyleneglycol) or a derivative thereof, and especially with a molecular weight in the range from about 10,000Da to about 40,000Da.
 - 10 The polymers of the present invention may be obtained commercially (for example from Nippon Oil and Fats; Nektar Therapeutics) or may be prepared from commercially available starting materials using conventional chemical procedures.
 - 15 Effector molecules of the present invention may be attached using standard chemical or recombinant DNA procedures in which the protein is linked either directly or via a coupling agent to the effector molecule. Particular chemical procedures include for example those described in International Patent Specification numbers WO 93/06231, WO92/22583, WO90/09195,
 - 20 WO89/01476, WO9915549 and WO03031581. Alternatively, where the effector molecule is a protein or polypeptide the linkage may be achieved using recombinant DNA procedures, for example as described in European Patent Specification No. 392745.
 - 25 In one example the effector molecules of the present invention may be attached to the protein through any available amino acid side-chain or terminal amino acid functional group located in the antibody fragment, for example any free amino, imino, thiol, hydroxyl or carboxyl group. Such amino acids may occur naturally in the antibody fragment or may be engineered into the fragment using
 - 30 recombinant DNA methods. See for example US 5,219,996. In a preferred aspect of the invention an effector molecule is covalently linked through a thiol
-

group of a cysteine residue located in the fragment. The covalent linkage will generally be a disulphide bond or, in particular, a sulphur-carbon bond. In one example where a thiol group is used as the point of attachment appropriately activated effector molecules, for example thiol selective derivatives such as maleimides and cysteine derivatives may be used.

In a preferred aspect of the present invention at least one of the effector molecules attached to the antibody fragment is a polymer molecule, preferably PEG or a derivative thereof. As regards attaching poly(ethyleneglycol) (PEG) moieties in general, reference is made to "Poly(ethyleneglycol) Chemistry, Biotechnical and Biomedical Applications", 1992, J.Milton Harris (ed), Plenum Press, New York; "Poly(ethyleneglycol) Chemistry and Biological Applications", 1997, J. Milton Harris and S.Zalipsky (eds), American Chemical Society, Washington DC and "Bioconjugation Protein Coupling Techniques for the Biomedical Sciences", 1998, M. Aslam and A. Dent, Grove Publishers, New York.

In one example of the present invention all the effector molecules are PEG and each molecule is covalently linked via a maleimide group to one or more thiol groups in the antibody fragment. The PEG may be any straight or branched molecule. To attach branched PEG molecules, a lysine residue is preferably covalently linked to the maleimide group. To each of the amine groups on the lysine residue is preferably attached a methoxy(poly(ethyleneglycol) polymer. In one example the molecular weight of each polymer is approximately 20,000Da and the total molecular weight of the entire polymer molecule is therefore approximately 40,000Da.

In the present invention two or more effector molecules are attached to the antibody fragment and at least one of said molecules is attached to a cysteine in the light chain or the heavy chain constant region. Suitable cysteines for attachment include naturally occurring cysteines present in the light and/or

heavy chain constant region and cysteines that have been engineered into the constant regions using recombinant DNA techniques. In one example two cysteines are engineered into the antibody fragment, one in each of the heavy and light chain constant regions. In one particular example these cysteines are engineered at positions whereby they can form a disulphide linkage with each other in the antibody starting material.

In one example of the present invention at least one effector molecule is attached to an interchain cysteine. The term interchain cysteine as used herein refers to a cysteine in the heavy or light chain constant region that would be disulphide linked to a cysteine in the corresponding heavy or light chain constant region in a naturally occurring antibody molecule. In particular the interchain cysteines of the present invention are a cysteine in the constant region of the light chain (C_L) and a cysteine in the first constant region of the heavy chain (C_{H1}) that are disulphide linked to each other in naturally occurring antibodies. Examples of such cysteines may typically be found at position 214 of the light chain and 233 of the heavy chain of human IgG1, as defined by Kabat *et al.*, 1987, in Sequences of Proteins of Immunological Interest, US Department of Health and Human Services, NIH, USA. It will be appreciated that the exact positions of these cysteines may vary from that of naturally occurring antibodies if any modifications, such as deletions, insertions and/or substitutions have been made to the antibody starting material. Hence according to one example of the present invention two or more effector molecules are attached to the antibody fragment and at least one of said molecules is attached to the interchain cysteine of C_L or the interchain cysteine of C_{H1} .

In the antibody fragments of the present invention, to which two or more effector molecules are attached, the heavy chain is not covalently bonded to the light chain. In these fragments there are no disulphide linkages between the heavy and the light chain and in particular the disulphide linkage found in naturally

occurring antibodies between the interchain cysteine of C_L and the interchain cysteine of C_H1 is absent.

In one example of the present invention the covalent linkage between the two interchain cysteines is absent as a result of one of the interchain cysteines being replaced with another amino acid, preferably an amino acid that does not contain a thiol group. By replace we mean that where the interchain cysteine would normally be found in the antibody fragment another amino acid is in its place. Examples of suitable amino acids include serine, threonine, alanine, glycine or any polar amino acid. A particularly preferred amino acid is serine. The methods for replacing amino acids are well known in the art of molecular biology. Such methods include for example site directed mutagenesis using methods such as PCR to delete and/or substitute amino acids or *de novo* design of synthetic sequences.

Hence according to one aspect of the present invention an effector molecule is attached to one of the interchain cysteines of C_L or C_H1 and additional effector molecules are attached elsewhere in the antibody fragment, in particular the constant region and/or the hinge region. Preferably additional effector molecules are attached to the hinge.

Particular fragments according to this aspect of the invention are those where:

- (i) an effector molecule is attached to the interchain cysteine of C_L and the interchain cysteine of C_H1 has been replaced by another amino acid or
- (ii) an effector molecule is attached to the interchain cysteine of C_H1 and the interchain cysteine of C_L has been replaced by another amino acid

In another example of the present invention an effector molecule is attached to at least one cysteine in the light chain constant region and at least one cysteine in the heavy chain constant region. As described above suitable cysteines include naturally occurring cysteines present in the light and/or heavy chain

constant region, such as the interchain cysteines of C_H1 and C_L and cysteines that have been engineered into the constant regions using recombinant DNA techniques. In one particular example each cysteine to which an effector molecule is attached would otherwise be linked to a cysteine in the
5 corresponding heavy or light chain via a disulphide bond if the effector molecules were not attached. In this example the covalent linkage between the two cysteines is removed during attachment of the effector molecules, as described herein, using a reducing agent. Additional effector molecules may be attached elsewhere in the antibody fragment, in particular the constant region
10 and/or the hinge using any of the methods described herein. Preferably additional effector molecules are attached to the hinge.

Particular fragments according to this aspect of the invention include those where:

- 15 (i) the cysteine residues in the heavy and light chain constant regions which are attached to effector molecules would otherwise be linked to each other via a disulphide bond if the effector molecules were not attached or
- (ii) the light chain cysteine to which an effector molecule is attached is the
20 interchain cysteine of C_L and the heavy chain cysteine to which an effector molecule is attached is the interchain cysteine of C_H1

Also provided by the present invention is an antibody Fab' fragment intermediate that is useful in producing some of the antibody fragments of the present
25 invention. Surprisingly it has been found that the interchain cysteine of C_L can form a disulphide linkage with a cysteine in the hinge region when the interchain cysteine of C_H1 has been substituted with a non-thiol containing amino acid. The presence of the disulphide linkage between the hinge cysteine and the C_L interchain cysteine allows the modified antibody Fab' fragment to be purified as
30 efficiently as Fab' fragments containing a native interchain disulphide by enabling the Fab' fragment to be extracted using heat extraction methods at

60°C or greater (see US 5,665,866). Hence according to this aspect of the invention there is provided an antibody Fab' fragment intermediate, characterized in that the C_H1 interchain cysteine has been replaced by a non-thiol containing amino acid and the C_L- interchain cysteine is covalently bonded to a cysteine in the hinge region. Any of the hinges previously described may be used in this intermediate but in particular the hinge region of said intermediate is of sufficient length and flexibility to enable a cysteine in said hinge to form a disulphide linkage with the interchain cysteine of C_L. Particularly useful hinges include a modified human γ 1 hinge in which only one cysteine is present, comprising the sequence DKTHTCPP or DKTHTCAA. Alternatively the hinge may contain two cysteines for example DKTHTCPPCPA or DKTHTCAACPA.

Also provided by the present invention is a host cell expressing the antibody Fab' fragment intermediate described above. Any suitable host cell/vector system may be used for the expression of the DNA sequences encoding the antibody Fab' intermediate of the present invention. Bacterial, for example *E.coli*, and other microbial systems may be used or eukaryotic, for example mammalian host cell expression systems may also be used. Suitable *E.coli* strains for use in the present invention may be naturally occurring strains or mutated strains capable of producing recombinant proteins. Examples of specific host *E.coli* strains include MC4100, TG1, TG2, DHB4, DH α , DH1, BL21, XL1Blue and W3110 (ATCC 27,325). Suitable mammalian host cells include CHO, myeloma or hybridoma cells.

Also provided by the present invention are methods for attaching effector molecules to the antibody Fab or Fab' fragment(s) of the present invention. In general the methods comprise:

- i) Treating an antibody Fab or Fab' fragment with a reducing agent capable of generating a free thiol group in a cysteine of the heavy and/or light chain constant region

- ii) Reacting the treated fragment with an effector molecule

In one aspect of the invention where the antibody Fab' intermediate described above is used there is provided a method of attaching two or more effector molecules to the antibody Fab' intermediate, said method comprising:

- i) Treating an antibody Fab' fragment with a reducing agent capable of reducing the covalent bond between the C_L interchain cysteine and a cysteine in the hinge region
- ii) reacting the treated fragment with an effector molecule

10

The methods provided by the present invention enable one or more effector molecule(s) to be attached to cysteines in the antibody fragment, in particular to cysteines in the constant region and the hinge. Two or more effector molecules can be attached to the antibody fragment using the methods described herein either simultaneously or sequentially by repeating the method.

15

The methods of the present invention also extend to one or more steps before and/or after the reduction methods described above in which further effector molecules are attached to the antibody fragment using any suitable method as described previously, for example via other available amino acids side chains such as amino and imino groups.

20

The reducing agent for use in the methods of the present invention is any reducing agent capable of reducing cysteines in the antibody fragment starting material to produce free thiols. Preferably the reducing agent efficiently reduces all available thiols. In one aspect of the present invention the reducing agent will need to be strong enough to reduce the interchain disulphide bond between cysteines of the heavy and light chain constant regions, for example, between the interchain cysteine of C_L and the interchain cysteine of C_H1, in order to allow attachment of effector molecules to said cysteines. Where the interchain disulphide bond is absent due to the absence of one of the interchain cysteines,

30

the reducing agent must be capable of efficiently liberating free thiols from the remaining cysteine(s). As the antibody molecules of the present invention have no requirement for the interchain disulphide bond stronger reducing agents can be used than are conventionally used with wild type antibody fragments. As a result a higher number of free thiols are produced and a higher proportion of the antibody fragments are correctly modified. The antibody fragments of the present invention can therefore be produced more efficiently and cost effectively than conventional antibody fragments. It will be clear to a person skilled in the art that suitable reducing agents may be identified by determining the number of free thiols produced after the antibody fragment is treated with the reducing agent. Methods for determining the number of free thiols are well known in the art, see for example Lyons *et al.*, 1990, Protein Engineering, 3, 703. Reducing agents for use in the present invention are widely known in the art for example those described in Singh *et al.*, 1995, Methods in Enzymology, 251, 167-73.

Particular examples include thiol based reducing agents such as reduced glutathione (GSH), β -mercaptoethanol (β -ME), β -mercaptoethylamine (β -MA) and dithiothreitol (DTT). Other methods for reducing the antibody fragments of the present invention include using electrolytic methods, such as the method described in Leach *et al.*, 1965, Div. Protein. Chem, 4, 23-27 and using photoreduction methods, such as the method described in Ellison *et al.*, 2000, Biotechniques, 28 (2), 324-326. Preferably however, the reducing agent for use in the present invention is a non-thiol based reducing agent capable of liberating one or more thiols in an antibody fragment. Preferably the non-thiol based reducing agent is capable of liberating all available thiols in an antibody fragment. Preferred reducing agents for use in the present invention are trialkylphosphine reducing agents (Ruegg UT and Fudinger, J., 1977, Methods in Enzymology, 47, 111-126; Burns J *et al.*, 1991, J.Org.Chem, 56, 2648-2650). Particular examples of which include tris(2-carboxyethyl)phosphine (TCEP), tris butyl phosphine (TBP), tris-(2-cyanoethyl) phosphine and tris-(2-hydroxyethyl) phosphine. Most preferably the reducing agent for use in the present invention is TCEP. It will be clear to a person skilled in the art that the concentration of

reducing agent for use in the present invention can be determined empirically, for example, by varying the concentration of reducing agent and measuring the number of free thiols produced. Typically the reducing agent for use in the present invention is used in excess over the antibody fragment for example
5 between 2 and 1000 fold molar excess. Preferably the reducing agent is in 2, 3, 4, 5, 10, 100 or 1000 fold excess. In one preferred example the reducing agent is in 4 molar excess.

The modified antibody fragments according to the invention may be prepared by
10 reacting an antibody fragment containing at least one reactive cysteine residue with an effector molecule, preferably a thiol-selective activated effector molecule. The reaction may generally be performed in a solvent, for example an aqueous buffer solution such as acetate or phosphate, at around neutral pH, for example around pH 4.5 to around pH 8.0. The reaction may generally be
15 performed at any suitable temperature, for example between about 5°C and about 70°C, for example at room temperature. The solvent may optionally contain EDTA at between 1 and 5mM, preferably 2mM. The effector molecule will generally be employed in excess concentration relative to the concentration of the antibody fragment. Typically the effector molecule is in between 2 and
20 100 fold molar excess, preferably 5, 10 or 50 fold excess.

Where necessary, the desired product containing the desired number of effector molecules may be separated from any starting materials or other product generated during the production process and containing an unwanted number of
25 effector molecules by conventional means, for example by chromatography techniques such as ion exchange, size exclusion or hydrophobic interaction chromatography.

Also provided by the present invention is a mixture containing two or more
30 antibody Fab or Fab' fragments, characterized in that the mixture is enriched for Fab or Fab' fragments in which the heavy chains in the fragments are not

covalently bonded to the light chains, the fragments have two or more effector molecules attached and at least one of said molecules is attached to a cysteine in the light chain or the heavy chain constant region. Said mixture may be produced using the methods provided by the present invention. By 'enriched' we mean that the antibody fragment with the desired number of effector molecules attached accounts for 50% or greater of the mixture. Preferably the antibody fragment with the desired number of effector molecules attached accounts for between 50 and 99% of the mixture. Preferably the mixtures are enriched by greater than 50%, preferably greater than 60%, more preferably greater than 70%. The proportion of such mixtures containing the antibody fragment with the desired number of effector molecules may be determined by using the size exclusion HPLC methods described herein. In one example the mixture is enriched with a Fab' fragment in which the heavy chain is not covalently bonded to the light chain and two or more effector molecules are attached to the fragment, wherein at least one effector molecule is attached to an interchain cysteine and at least one effector molecule is attached to the hinge region.

The antibody fragments according to the invention may be useful in the detection or treatment of a number of diseases or disorders. Such diseases or disorders may include those described under the general heading of infectious disease, e.g. bacterial infection; fungal infection; inflammatory disease/autoimmunity e.g. rheumatoid arthritis, osteoarthritis, inflammatory bowel disease; cancer; allergic/atopic disease e.g. asthma, eczema; congenital disease, e.g. cystic fibrosis, sickle cell anemia; dermatologic disease e.g. psoriasis; neurologic disease, e.g. multiple sclerosis; transplants e.g. organ transplant rejection, graft-versus-host disease; and metabolic/idiopathic disease e.g. diabetes.

The antibody fragments according to the invention may be formulated for use in therapy and/or diagnosis and according to a further aspect of the invention we

provide a pharmaceutical composition comprising an antibody Fab or Fab' fragment in which the heavy chain in the fragment is not covalently bonded to the light chain characterized in that two or more effector molecules are attached to the fragment and at least one of said molecules is attached to a cysteine in the light chain or the heavy chain constant region, together with one or more pharmaceutically acceptable excipients, diluents or carriers.

EXAMPLES

The present invention will now be described by way of example only, in which reference is made to:

Figure 1: Proportions of multi-PEGylated, mono-PEGylated and unPEGylated g165Fab' LC-C HC-C, hinge-CAA produced using various reductants as determined by size exclusion HPLC.

Figure 2: Proportions of multi-PEGylated, mono-PEGylated and unPEGylated g165Fab' variants produced using TCEP as the reductant, as determined by size exclusion HPLC.

Figure 3a: Non-reducing SDS-PAGE of PEGylated g165 Fab' variants

Figure 3b: Non-reducing SDS-PAGE of purified g165 Fab' variants.

Figure 4: Pharmacokinetics of intravenously dosed ¹²⁵I labelled PEGylated Fab' in rats

Figure 5: Neutralisation of intraperitoneal dosed antigen-induced neutrophil accumulation by intravenous pre-dosing of Fab'-PEG in mice.

Fab' nomenclature and general methods

The Fab and Fab' molecules used in the following examples are g165 which binds to a human cell surface receptor and g8516 which binds to the human cytokine IL-1 β . The nomenclature for each fragment uses the single letter code C for cysteine and S for serine to denote the amino acid at the site of the inter-

chain cysteine of C_L in the light chain (LC) and the site of the inter-chain cysteine of C_H1 in the heavy chain (HC). For example, a normal Fab' is 'g165 Fab' LC-C HC-C, hinge-CAA' whereas the version in which the inter-chain cysteine of CH1 has been substituted with a serine so there is no inter-chain disulphide is eg. 'g165 Fab' LC-C HC-S, hinge-CAA'. A full γ 1 middle hinge is noted as 'hinge-CPPCPA'. A list of the plasmids used in the following examples are shown in Table 1.

Table 1. Plasmid and protein details.

Plasmid	Protein	Disulphide structure	Relative purified yields	
			30°C	60°C
PDPH147	g165 Fab' LC-C, HC-C, hinge-CAA	LC-GE HC-KS DKTHT AA	100%	77%
PDPH224	g165 Fab' LC-S, HC-C, hinge-CAA	LC-GE HC-KS DKTHT AA	100%	19%
PDPH225	g165 Fab' LC-C, HC-S, hinge-CAA	LC-GE HC-KS DKTHT AA	100%	97%
PDPH226	g165 Fab' LC-C, HC-C, hinge-SAA	LC-GE HC-KS DKTHT SAA	100%	78%
PDPH238	g8516 Fab' LC-C, HC-C, hinge CPPCPA	LC-GE HC-KS DKTHT PP CPA	Nd	nd
PDPH252	g8516 Fab' LC-C, HC-S, hinge-CAA	LC-GE HC-KS DKTHT AA	100%	75.1%
PDPH262	g8516 Fab' LC-C, HC-C no hinge	LC-GE HC-KS	100%	100%

Production of Fab'

Fab' molecules of the present invention were produced in *E.coli* strain W3110 and purified using standard methods (Humphreys et al., 2002, Protein Expression and Purification, 26, 309-320). PCR mutagenesis was used to change the interchain cysteines of C_L and C_H1 to serines.

Reduction and PEGylation of Fab'.

All reductions and PEGylations were performed in 0.1M Phosphate pH6.0; 2mM EDTA. The concentration of Fab' and reductant were as stated in each example. In all cases reduction was done for 30 minutes at room temperature

(~24°C), the proteins desalted on a PD-10 column (Pharmacia) and then mixed with 5 fold molar excess of PEG-maleimide over Fab'. The 40kDa PEG was from Nektar and 20 and 30kDa PEG was from Nippon Oils and Fats (NOF). PEGylated Fab' was separated from unpegylated Fab' by size exclusion HPLC on analytical Zorbax GF-450 and GF-250 columns in series. These were developed with a 30min isocratic gradient of 0.2M phosphate pH 7.0 + 10% ethanol at 1ml/min and Fab' detected using absorbance at 214nm and 280nm.

Example 1 Creation of novel PEGylated Fab' fragments

A tri-PEGylated antibody Fab' fragment was produced by reducing the inter-chain disulphide of the antibody fragment g165 Fab' LC-C HC-C, hinge-CAA and attaching PEG molecules to the available thiols of the inter-chain cysteines of C_L and C_{H1} and the hinge cysteine. A number of different reductants were tested. The thiol based reductants reduced glutathione (GSH), β -mercaptoethanol (β -ME), β -mercaptoethylamine (β -MA) and dithiothreitol (DTT) and the non-thiol based reductant tris carboxyethyl phosphine (TCEP).

The g165 Fab' LC-C HC-C, hinge-CAA was at 10mg/ml and the reductants were at 5mM and the number of PEG molecules attached to the fragments was determined by size exclusion HPLC (Figure 1). PEGylation was expected to occur on all three available cysteines if the inter-chain disulphide was reduced. TCEP resulted in ~65% multi-PEGylation whilst DTT only resulted in approximately 15% multi-PEGylated material and β -MA, β -ME and GSH only resulted in trace amounts (<1%) of multi-PEGylation. The thiol based reductants typically resulted in monoPEGylated Fab' as these reductants were not strong enough to reduce the inter-chain disulphide bond. These are the reductants typically used in the production of PEGylated antibody fragments where the interchain disulphide is retained. The low efficiency of mono PEGylation achieved using these reductants was observed here, 55% for DTT, 52% β MA, 20% β ME and 22% GSH.

In another example, the inter-chain disulphide linkage between the heavy and the light chain was removed by replacing either the interchain cysteine of C_L or the interchain cysteine of C_H1 with serine. Each antibody fragment at 10mg/ml was reduced with 5mM TCEP, desalted and then reacted with 40kDa PEG-maleimide. The results in Figures 2 and 3 show that all of the cysteines were highly accessible to the PEG maleimide. In all cases the predicted number of thiols (2 or 3) were accessible after reduction with TCEP allowing efficient site specific PEGylation to occur. Figure 3b shows the unPEGylated purified Fab' fragments. Figure 3a illustrates the increase in molecular weight associated with the attachment of two or more PEG molecules. Lane 1 corresponds to LC-C HC-C, hinge CAA where two PEG molecules are attached to the heavy chain and one to the light chain. The highest molecular weight band in lane 1 is the heavy chain with two PEG molecules attached, the next band is a small amount of the heavy chain with only one PEG molecule attached and the next band is the light chain with only one PEG molecule attached. Lane 3 corresponds to Fab' LC-S HC-C, hinge CAA in which there are two PEG molecules attached to the heavy chain. The highest molecular weight band in lane 3 is the heavy chain with two PEG molecules attached while the lower molecular weight band is free light chain with no PEG molecules attached. Lane 4 corresponds to Fab' LC-C HC-S, hinge CAA in which there is one PEG on the heavy and the light chain. The two high molecular weight bands very close together are heavy and light chain with one PEG molecule attached. The lower band is a small amount of presumed covalent light chain dimer with no PEG attached. Lane 5 is the same as lane 4 in that a single PEG is attached to each chain of Fab' LC-C HC-C, hinge SAA. Lane 6 is the control in which there is no interchain disulphide and no PEG molecules attached, Fab' LC-S HC-S, hinge SAA. The one major band observed is that of non-covalently associated heavy and light chains.

In all cases >65% of Fab' molecules were multi PEGylated with either 2 or 3 PEG molecules. The modified antibody fragments of the present invention can

therefore be produced more efficiently than conventional antibody fragments where the interchain disulphide is retained.

5 The non-thiol based reductant tris carboxyethyl phosphine (TCEP) was shown to be a more efficient reducing agent than the thiol based reductants reduced glutathione (GSH), β -mercaptoethanol (β -ME), β -mercaptoethylamine (β -MA) and dithiothreitol (DTT). TCEP is therefore a useful reducing agent for producing the modified antibody fragments of the present invention.

10 **Example 2 Stability tests of Fab' lacking inter CL: C_H1 disulphide**
Effect of lack of inter CL: C_H1 disulphide bonds on the physical performance of Fab' and Fab-PEG.

i) Purification of Fab'

15 Antibody fragments produced in *E.coli* are usually extracted from the periplasm by shaking overnight in Tris / EDTA at 30°C or 60°C. The high temperature heat extraction facilitates the extraction and partial purification from *E.coli* proteins of antibody fragments (see US 5,665,866). We observed that yields of Fab' in which the light chain cysteine had been substituted for serine were reduced in
 20 the order of 80% when the incubation was done at 60°C relative to that of 30°C (Table 1). Surprisingly, where the heavy chain cysteine was substituted for serine stability was greater than 95% at 60°C which indicated that the Fab' LC-C HC-S, hinge-CAA had a long and flexible enough hinge to efficiently form a disulphide between C_L and the hinge, making this a useful intermediate in the production of
 25 diPEGylated Fab' molecules as this can be purified using the heat extractions described above. Non reducing SDS-PAGE of such Fab' (Lane 4, Figure 3b) also demonstrate a covalent linkage between LC and HC. Figure 3b shows that in lane 3, LC-S HC-C, hinge CAA is present as free heavy and light chain whereas in lane 4 LC-C HC-S, hinge CAA the heavy and light chains are
 30 covalently linked, giving this Fab' the same migration as a Fab' in which the native interchain disulphide is present e.g. lane 1, Fab' LC-C HC-C, hinge CAA.

Fab' engineered to lack inter C_L:C_H1 disulphide bonds were purified using protein G or ion exchange in exactly the same manner as Fab' containing inter C_L:C_H1 disulphide bonds. Since these involved elution at pH 2.7 (protein G) or equilibration at pH 4.5 (ion exchange) the Fab' interaction between C_L:C_H1 was clearly physico-chemically stable.

ii) Antigen binding affinity *in vitro*.

g165 Fab' with PEG molecules attached in the presence or absence of a covalent linkage between the light chain the heavy chain were analysed for antigen affinity using BIAcore™. Antigen was captured on a BIAcore™ chip and the antibodies passed over in the solution phase and an affinity determined.

Table 2. Antigen affinity of mono, di- and tri- PEGylated Fab' *in vitro*.

SAMPLE	Fab'	ka e5 (1/Ms)	kd e-4 (1/s)	KD nM
147	g165 LC-C HC-C, hinge-CAA	6.6	8.5	1.3
224	g165 LC-S HC-C, hinge-CAA	6.6	10.5	1.6
225	g165 LC-C HC-S, hinge-CAA	6.7	8.5	1.3
226	g165 LC-C HC-C, hinge-SAA	5.3	7.6	1.4
147 1x40 PEG	g165 LC-C HC-C, hinge-CAA	6.5	11.9	1.8
147 3x20 PEG	g165 LC-C HC-C, hinge-CAA	6.8	13.3	1.9
225 2x20 PEG	g165 LC-C HC-S, hinge-CAA	8.2	11.9	1.4
225 2x30 PEG	g165 LC-C HC-S, hinge-CAA	8.1	13.4	1.6

Table 2 shows that neither the lack of inter $C_L:C_H1$ disulphide or presence of mono- di- or tri- PEGylation materially affects the binding affinity.

5 **Example 3 Pharmacokinetics of Fab-PEG in rats.**

Circulating half life of Fab PEGylated on both polypeptides in animals.

10 ^{125}I labelled PEGylated Fab' molecules were injected intravenously into rats and the serum permanence of potential therapeutic Fab' determined. The circulating half life of non-PEGylated Fab' is very short ($t_{1/2\beta} \approx 30$ minutes) and that of free LC or HC is likely to be shorter still.

300 μ g of Fab'-PEG per animal group was ^{125}I -labelled using Bolton and Hunter reagent (Amersham) to a specific activity of 0.22 - 0.33 μ Ci/ μ g.

15 Male Sprague Dawley rats of 220-250 g (Harlan) were injected *intra venously* or *sub cutaneously* with 20 μ g ^{125}I -labelled Fab'-PEG variants whilst under Halothane anaesthesia (n = 6 per group). Serial arterial bleeds from the tail were taken at 0.5, 2, 4, 6, 24, 48, 72 and 144 hours post administration.

20 Samples were counted using a COBRATM Autogamma counter (Canberra Packard). Data were plotted and Area Under Curve were calculated using GraphPad Prism (GraphPad Software Incorporated) and is expressed as % injected dose.hour (% i.d/hr). The $t_{1/2\alpha}$ is defined by time points 0.5, 2, 4, and 6, whilst the $t_{1/2\beta}$ is defined by time points 24, 48, 72 and 144.

25 To test whether the non-covalent association between C_L and C_H1 would be disturbed by the steric issues relating to the maleimide linker and PEG, g165 Fab' LC-C HC-S, hinge-CAA was di-PEGylated with both 20 and 30kDa PEG using TCEP as the strong reducing agent. In addition, a normal g165 Fab' LC-C HC-C, hinge-CAA was tri-PEGylated with 20kDa PEG by virtue of a very strong
30 reduction with TCEP. The data in Table 2 and Figure 4 show that although the

final PEGylated forms of these Fab' have non-covalently associated LC and HC the circulating half life is comparable to that of a mono-PEGylated control.

5 Table 3. Pharmacokinetic analysis of Fab-PEG in rat model.

Fab	PEG	Admin.	$t_{1/2\alpha}$ (h)	$T_{1/2\beta}$ (h)	AUC (0- ∞) (%dose*h)
G8516 Fab' LC-C HC-C Hinge-CAA	1x40kDa (branched)	<i>i.v.</i>	4.76 \pm 1.3	48 \pm 2.8	4554 \pm 268
G165 Fab' LC-C HC-S hinge-CAA	2x20kDa	<i>i.v.</i>	-	31 \pm 2.8	4786 \pm 353
G165 Fab' LC-C HC-S hinge-CAA	2x30kDa	<i>i.v.</i>	-	39 \pm 2.0	6154 \pm 369
G165 Fab' LC-C HC-C hinge-CAA	3x20kDa	<i>i.v.</i>	-	38 \pm 1.1	6171 \pm 693

Example 4: Mouse antigen binding efficacy models: *In vivo* efficacy in animal models. *i.v.* dosed g8516 Fab'-PEG and intraperitoneal dosed hIL-1 β .

Male Balb/c mice (21g) were injected intravenously (*i.v.*) with a single dose (3 mg/kg in 100 μ l PBS) of g8516 Fab'LC-C HC-C hinge-CAA-40kDa PEG, g8516 Fab'LC-C HC-S hinge-CAA-2x20kDa PEG, or ghA33 Fab'LC-C HC-C hinge-CAA-40kDa PEG (irrelevant control), 7 and 14 days prior to an *i.p.* injection of hIL-1 β (3 ng/kg in 100 μ l PBS vehicle). After 120 minutes, mice were killed by cervical dislocation and peritoneal lavage was performed (3ml PBS + 0.25% BSA, 12mM HEPES). A total leukocyte count was performed using a Coulter Counter. For identification of neutrophils, 50 μ l peritoneal lavage fluid was stained with 1:300 dilution of anti-CD45-CyChrome mAb and 1:300 dilution of anti-GR-1-PE mAb (anti-Ly6G/Ly6C) for 20 minutes (4°C, in the dark). Leukocytes were washed once in PBS (0.25% BSA, 12mM HEPES), resuspended in 300 μ l PBS (0.25% BSA, 12mM HEPES) and analysed by flow cytometry. Neutrophils were identified as CD45⁺GR-1^{HIGH}.

Figure 5 shows that there was no difference between g8516 Fab-PEG that have, or lack inter $C_L:C_H1$ disulphide bonds at either of the time points. This demonstrates that efficacy is retained during 1 week in the mouse circulation and therefore by implication that LC and HC remain associated during this time.

5

From the above examples it can clearly be seen that the novel PEGylated molecules of the present invention can be produced more efficiently than PEGylated antibodies that contain an inter $C_L:C_H1$ disulphide bond. The examples also demonstrate that PEGylation of Fab' which lack the interchain disulphide bond has no adverse effects on the biological activity or stability of the antibody Fab' making these useful therapeutic molecules which can be produced more efficiently than conventional Fab'.

10

CLAIMS

1. An antibody Fab or Fab' fragment in which the heavy chain in the
fragment is not covalently bonded to the light chain characterized in that
5 two or more effector molecules are attached to the fragment and at least
one of said molecules is attached to a cysteine in the light chain or the
heavy chain constant region.
 2. The antibody fragment of claim 1 wherein one of the effector molecules is
attached to the interchain cysteine of C_L or the interchain cysteine of C_H1.
 - 10 3. The antibody fragment of claim 2 wherein an effector molecule is
attached to the interchain cysteine of C_L and the interchain cysteine of
C_H1 has been replaced by another amino acid.
 4. The antibody fragment of claim 3 wherein the interchain cysteine of C_H1
has been replaced with an amino acid that does not contain a thiol group.
 - 15 5. The antibody fragment of claim 4 wherein the interchain cysteine of C_H1
has been replaced by serine.
 6. The antibody fragment of claim 2 wherein an effector molecule is
attached to the interchain cysteine of C_H1 and the interchain cysteine of
C_L has been replaced by another amino acid.
 - 20 7. The antibody fragment of claim 6 wherein the interchain cysteine of C_L
has been replaced with an amino acid that does not contain a thiol group.
 8. The antibody fragment of claims 7 wherein the interchain cysteine of C_L
has been replaced with serine.
 9. The antibody fragment of claim 1, wherein an effector molecule is
25 attached to a cysteine in the light chain constant region and a cysteine in
the heavy chain constant region.
 10. The antibody fragment of claim 9, wherein the cysteine residues in the
heavy and light chain constant regions which are attached to effector
molecules would otherwise be linked to each other via a disulphide bond
30 if the effector molecules were not attached.
-

11. The antibody fragment of claim 10 where the light chain cysteine to which an effector molecule is attached is the interchain cysteine of C_L and the heavy chain cysteine to which an effector molecule is attached is the interchain cysteine of C_{H1} .
- 5 12. The antibody fragment of claims 1-11 where the interchain cysteine of C_L is at position 214 of the light chain and the interchain cysteine of C_{H1} is at position 233 of the heavy chain.
13. An antibody Fab' fragment according to claims 1-12 that contains a modified hinge region.
- 10 14. An antibody Fab' fragment according to claims 1-13 wherein an effector molecule is attached to at least one cysteine in the hinge region.
15. A method of producing an antibody Fab' or Fab fragment according to claims 1-14 comprising:
- 15 a. Treating an antibody Fab or Fab' fragment with a reducing agent capable of generating a free thiol group in a cysteine of the heavy and/or light chain constant region
- b. Reacting the treated fragment with an effector molecule
16. An antibody Fab' fragment, characterized in that the C_{H1} interchain cysteine has been replaced by a non-thiol containing amino acid and the
- 20 C_L interchain cysteine is covalently bonded to a cysteine in the hinge region.
17. A method of attaching two or more effector molecules to the antibody fragment of claim 16 comprising:
- 25 a. Treating an antibody Fab' fragment with a reducing agent capable of reducing the covalent bond between the C_L interchain cysteine and a cysteine in the hinge region
- b. reacting the treated fragment with an effector molecule
18. The method according to claims 15 and 17 in which the reducing agent is a non-thiol based reductant.
- 30 19. The method according to claims 15 and 17 where the non-thiol based reductant is TCEP.
-

20. A mixture containing two or more antibody Fab or Fab' fragments, characterized in that the mixture is enriched for Fab or Fab' fragments in which the heavy chains in the fragments are not covalently bonded to the light chains, the fragments have two or more effector molecules attached and at least one of said molecules is attached to a cysteine in the light chain or the heavy chain constant region.
21. The mixture of claim 20 in which greater than 50% of the mixture comprises a Fab' or Fab fragment in which the heavy chain in the fragment is not covalently bonded to the light chain, the fragment has two or more effector molecules attached and at least one of said molecules is attached to a cysteine in the light chain or the heavy chain constant region.
22. The antibody fragment of claims 1-15 and 17-21 wherein the effector molecule is PEG
23. A host cell expressing the antibody fragment of claim 16.
24. A pharmaceutical composition comprising an antibody fragment according to any of the proceeding claims, together with one or more pharmaceutically acceptable excipients, diluents or carriers.
-

Figure 1




Figure 2.




Figure 3.






Figure 4.



5/5

Figure 5.



PA/PP

n=7-8 Balb/c mice/group

3mg/kg mAb i.v. t=-14, -7 days

3ng/kg hIL-1 β i.p. at t=0

peritoneal lavage t=+120min

*** p<0.001 compared control mAb

■ gA33(LC-C, HC-C, hinge-CAA)Fab'-PEG(1x40k)

▨ g8516(LC-C, HC-C, hinge-CAA)Fab'-PEG(1x40k)

▩ g8516(LC-C, HC-S, hinge-CAA)Fab'-PEG(2x20k)

THE PATENT OFFICE

09 JUL 2004

Received in Patents
International Unit

PCT/GB2004/002810

